Jay Flatley has served as CEO and as a director of Illumina since October 1999.

He drives the strategic vision for the company and manages its commercial and corporate functions.

Until December 2013, he served in the dual role of president and CEO leading the company through a period of tremendous growth.

With the company’s initial success in genotyping and subsequent expansion into whole-genome sequencing, diagnostics and informatics, sales grew from $1.3 million in 2000 to more than $1.42 billion in 2013.

Under Mr. Flatley’s leadership, the company launched over 50 major products, acquired several new technologies and entered multiple markets in the research, applied and clinical arenas.

Illumina is now uniquely positioned to unlock the power of the genome, as the leading provider of genetic analysis technologies.

^[0]